Pilot Study of a Novel 18F-labeled FSHR Probe for Tumor Imaging
详细信息 查看全文
- 作者：Yuping Xu (1)
Donghui Pan (1)
Chen Zhu (2)
Qing Xu (2)
Lizhen Wang (1)
Fei Chen (1)
Runlin Yang (1)
Shineng Luo (1)
Min Yang (1)
Yongjun Yan (3) - 关键词：FSHR ; PET ; Tumor ; 18F ; Al ; NOTA ; MAL ; FSH1 ; FSHβ(33-3) ; Radiolabel
- 刊名：Molecular Imaging and Biology
- 出版年：2014
- 出版时间：August 2014
- 年：2014
- 卷：16
- 期：4
- 页码：578-585
- 全文大小：685 KB
- 参考文献：1. Robinson LJ, Tourkova I, Wang Y et al (2010) FSH-receptor isoforms and FSH-dependent gene transcription in human monocytes and osteoclasts. Biochem Biophys Res Commun 394:12-7 CrossRef
2. Simoni M, Gromoll J, Nieschlag E (1997) The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology. Endocr Rev 18:739-73
3. Gartrell BA, Tsao CK, Galsky MD et al (2013) The follicle-stimulating hormone receptor: a novel target in genitourinary malignancies. Urol Oncol: Semin Orig Inv 31:1403-407 CrossRef
4. Radu A, Pichon C, Camparo P et al (2010) Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 363:1621-630 CrossRef
5. Siraj A, Desestret V, Antoine M et al (2013) Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases. BMC Cancer 13:246 CrossRef
6. Siraj MA, Pichon C, Radu A et al (2012) Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib. J Cell Mol Med 16:2010-016 CrossRef
7. Grasso P, Santa-Coloma TA, Reichert LE Jr (1991) Synthetic peptides corresponding to human follicle stimulating hormone (hFSH)-h-(1-15) and hFSH-h-(51-65) induce uptake of 45Ca++ by liposomes: evidence for calcium-conducting transmembrane channel formation. Endocrinology 128:2745-751 CrossRef
8. Agris PF, Guenther RH, Sierzputowska-Gracz H et al (1992) Solution structure of a synthetic peptide corresponding to a receptor binding region of FSH (hFSH-β33-53). J Protein Chem 11:495-07 CrossRef
9. Zhang XY, Chen J, Zheng YF et al (2009) Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma / in vivo. Cancer Res 69:6506-514 CrossRef
10. Zaheer A, Cho SY, Pomper MG (2009) New agents and techniques for imaging prostate cancer. J Nucl Med 50:1387-390 CrossRef
11. Hong H, Zhang Y, Sun JT et al (2010) Positron emission tomography imaging of prostate cancer. Amino Acids 39:11-7 CrossRef
12. Fani M, Maecke HR (2012) Radiopharmaceutical development of radiolabelled peptides. Eur J Nucl Med Mol Imaging 39:S11–S30 CrossRef
13. Laverman P, D'Souza CA, Eek A et al (2012) Optimized labeling of NOTA-conjugated octreotide with F-18. Tumour Biol 33:427-34 CrossRef
14. Liu S, Liu H, Jiang H et al (2011) One-step radiosynthesis of 18F-AlF-NOTA-RGD2 for tumor angiogenesis PET imaging. Eur J Nucl Med Mol Imaging 38:1732-741 CrossRef
15. Dijkgraaf I, Franssen GM, McBride WJ et al (2012) PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog. J Nucl Med 53:947-52 CrossRef
16. Wan W, Guo N, Pan D et al (2013) First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med 54:691-98 CrossRef
17. Ait-Mohand S, Fournier P, Dumulon-Perreault V et al (2011) Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates. Bioconjug Chem 22:1729-735 CrossRef
18. Yang M, Gao H, Zhou Y et al (2011) 18F-labeled bombesin receptor agonist and antagonist: a comparative study in prostate cancer imaging. Theranostics 1:220-29 CrossRef
19. Ambrosini V, Fani M, Fanti S et al (2011) Radiopeptide imaging and therapy in Europe. J Nucl Med 52:42S-5S CrossRef
20. Graham MM, Menda Y (2011) Radiopeptide imaging and therapy in the United States. J Nucl Med 52:56S-3S CrossRef
21. Koopmans KP, Glaudemans AW (2012) Rationale for the use of radiolabelled peptides in diagnosis and therapy. Eur J Nucl Med Mol Imaging 39:S4–S10 CrossRef
22. McBride WJ, D'Souza CA, Karacay H et al (2012) New lyophilized kit for rapid radiofluorination of peptides. Bioconjug Chem 23:538-47 CrossRef
23. Lang L, Li W, Guo N et al (2011) Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem 22:2415-422 CrossRef
24. McBride WJ, Sharkey RM, Karacay H et al (2009) A novel method of 18F radiolabeling for PET. J Nucl Med 50:991-98 CrossRef
25. Kiesewetter DO, Guo N, Guo J et al (2012) Evaluation of an [18F]AlF-NOTA analog of exendin-4 for imaging of GLP-1 receptor in insulinoma. Theranostics 2:999-009 CrossRef
26. Mariani S, Salvatori L, Basciani S et al (2006) Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. J Urol 175:2072-077 CrossRef
27. Parry JJ, Kelly TS, Andrews R et al (2007) / In vitro and / in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties. Bioconjug Chem 18:1110-117 CrossRef - 作者单位：Yuping Xu (1)
Donghui Pan (1)
Chen Zhu (2)
Qing Xu (2)
Lizhen Wang (1)
Fei Chen (1)
Runlin Yang (1)
Shineng Luo (1)
Min Yang (1)
Yongjun Yan (3)
1. Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, 214063, China
2. Nanjing Medical University, Nanjing, Jiangsu, 210029, China
3. Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA - ISSN：1860-2002
文摘
Purpose Follicle-stimulating hormone receptor (FSHR) is overexpressed in primary and metastatic tumor. Molecular imaging of FSHR is beneficial for prognosis and therapy of cancer. FSHβ(33-3) (YTRDLVYKDPARPKIQKTCTF), denoted as FSH1, is a FSHR antagonist. In the present study, maleimide-NOTA conjugate of FSH1 (NOTA-MAL-FSH1) was designed and labeled with [18F] aluminum fluoride. The resulting tracer, 18F-Al-NOTA-MAL-FSH1, was preliminarily evaluated in PET imaging of FSHR-positive tumor. Procedures NOTA-MAL-FSH1 was synthesized and radiolabeled with Al18F complex. The tumor-targeting potential and pharmacokinetic profile of the 18F-labeled compound were evaluated in vitro and in vivo using a PC3 human prostate tumor model. Results 18F-Al-NOTA-MAL-FSH1 can be efficiently produced within 30?min with a non-decay-corrected yield of 48.6?±-.1?% and a radiochemical purity of more than 95?%. The specific activity was at least 30?GBq/μmol. The radiotracer was stable in phosphate-buffered saline and human serum for at least 2?h. The IC50 values of displacement 18F-Al-NOTA-MAL-FSH1 with FSH1 were 252?±-.12?nM. The PC3 human prostate tumor xenografts were clearly visible with high contrast after injection of 18F-Al-NOTA-MAL-FSH1 via microPET. At 30, 60 and 120?min postinjection, the tumor uptakes were 2.98?±-.29?% injected dose (ID)/g, 2.53?±-.20?%ID/g and 1.36?±-.12?%ID/g, respectively. Dynamic PET scanning showed that tumor uptake reached a plateau by about 6?min. Heart peaked earlier and then cleared quickly. Biodistribution studies confirmed that the normal organs except kidney uptakes were all below 1?%ID/g at 1?h p.i. The tumor-to-blood and tumor-to-muscle ratio at 10?min, 0.5, 1, and 2?h after injection were 1.64?±-.36, 2.97?±-.40, 9.31?±-.06, and 13.59?±-.33 and 7.05?±-.10, 10.10?±-.48, 16.17?±-.29, and 30.88?±-.67, respectively. The tracer was excreted mainly through the renal system, as evidenced by high levels of radioactivity in the kidneys. FSHR-binding specificity was also demonstrated by reduced tumor uptake of 18F-Al-NOTA-MAL-FSH1 after coinjection with an excess of unlabeled FSH1 peptide. Conclusion NOTA-MAL-FSH1 could be labeled rapidly and efficiently with 18F using one step method. Favorable preclinical data suggest that 18F-Al-NOTA-MAL-FSH1 may be a suitable radiotracer for the non-invasive visualization of FSHR positive tumor in vivo.